Min-Jung Lee

Min-Jung Lee

Auto-generated profile, based on publicly available information

Min-Jung Lee

National Cancer Institute 1 Developmental Therapeutics Branch, Center for Cancer Research , Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MAMelissa L. Abel
Melissa L. Abel
NTNobuyuki Takahashi
Nobuyuki Takahashi
CPCody Peer
Cody Peer
CRChristophe Redon
Christophe Redon
SNSamantha Nichols
Samantha Nichols
ATAnish Thomas
Anish Thomas
Purpose: Despite promising preclinical studies, toxicities have precluded combinations of chemotherapy and DNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted chemotherapy delivery might enable clinical translation of such combinations. Patients and Methods: In a phase I trial, we combined sacituzumab govitecan, antibody–drug conjugate (ADC) that delivers topoisomerase-1 inhibitor SN-38 to tumors expressing Trop-2, with ataxia telangiectasia and Rad3-related (ATR) inhibitor berzosertib. Twelve patients were enrolled across three dose levels. Results: Treatment was well tolerated, with improved safety over conventional chemotherapy-based combinations, allowing escalation to the highest dose. No dose-limiting toxicities or clinically relevant ≥grade 4 adverse events occurred. Tumor regressions were observed in 2 patients with neuroendocrine prostate cancer, and a patient with small cell lung cancer transformed from EGFR-mutant non–small cell lung cancer. Conclusions: ADC-based delivery of cytotoxic payloads represents a new paradigm to increase efficacy of DDR inhibitors. See related commentary by Berg and Choudhury, p. 3557

18 June 2015 in Investigational New Drugs
Verified
Journal Article
Open access
PDF file
KDKhanh Do
Khanh Do
GSGiovanna Speranza
Giovanna Speranza
LCLun-Ching Chang
Lun-Ching Chang
EPEric C. Polley
Eric C. Polley
RBRachel Bishop
Rachel Bishop
Shivaani KummarShivaani Kummar
Shivaani Kummar
Summary Inhibition of heat shock 90 (Hsp90) molecular chaperones allows targeting of multiple proteins involved in tumorigenesis. We investigated the safety, recommended phase 2 dose (RP2D), and pharmacokinetic and pharmacodynamic profile of onalespib (AT13387), a potent synthetic Hsp90 inhibitor, administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/week) in a phase I trial. This study followed an accelerated titration design with a starting dose of 20 mg/m2/dose and a standard 3 + 3 dose escalation design for dose level 4 (120 mg/m2/dose) and above. Additional patients were enrolled at the RP2D with mandatory paired tumor biopsies to assess modulation of 210 client proteins using reverse phase protein array analysis. Thirty-one patients were treated; RP2D was established at 160 mg/m2/dose on the QDx2/week schedule. Common toxicities were gastrointestinal, hepatic, and hematologic. Pharmacokinetic profile was linear and plasma levels increased proportionally with dose (T½ ~8 h). No responses were observed; eight patients had stable disease for > 2 cycles with one patient remaining on study for 6 cycles. Target engagement was demonstrated by transcriptional upregulation of Hsp70 and Hsp27 in PBMCs. Statistically significant modulation of client proteins was not achieved in the 9 paired tumor biopsies evaluated; however, hierarchical clustering revealed two subgroups of patients with differential patterns of protein expression. Further combination studies are needed in order to target prospective driver oncoproteins.

1 April 2016 in Journal of Urology
Verified
Journal Article
Open access
EKEric C. Kauffman
Eric C. Kauffman
MLMin-Jung Lee
Min-Jung Lee
SASylvia V. Alarcon
Sylvia V. Alarcon
SLSunmin Lee
Sunmin Lee
AHAnthony N. Hoang
Anthony N. Hoang
PPPeter A. Pinto
Peter A. Pinto
Purpose: While the significance of circulating tumor cells in clinically localized cancer remains controversial, it has been reported that surgical tumor manipulation can increase circulating tumor...

5 June 2015 in Oncology Letters
Verified
Journal Article
Open access
PDF file
HGHelen Gharwan
Helen Gharwan
YTYusuke Tomita
Yusuke Tomita
MLMin-Jung Lee
Min-Jung Lee
ATAnish Thomas
Anish Thomas
ABArlene Berman
Arlene Berman
ARArun Rajan
Arun Rajan
The most frequently described glomerulopathy in patients with thymoma is minimal change disease (MCD). The present study reports the case of a 63-year-old female with recurrent thymoma and poorly-controlled paraneoplastic MCD, who was enrolled on a phase I/II clinical trial (no. NCT01100944) and treated with the histone deacetylase inhibitor, belinostat, in combination with cisplatin, doxorubicin and cyclophosphamide. Treatment resulted in a complete radiological response, a dramatic reduction in proteinuria and changes in immune cell subset composition, consisting of a reduction in the number of T helper (Th)1, Th2, Th17 and regulatory T cells. Changes in T-cell polarization were also observed with an increase in the Th1/Th2 ratio. To the best of our knowledge, the current study is the first to provide a detailed description of changes in immune cell subset composition in thymoma-associated MCD. Early administration of effective antitumor therapy should be considered in these cases, particularly when proteinuria is poorly controlled despite the use of steroids and other immunosuppressive therapies.

8 January 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
AKAeRang Kim
AeRang Kim
KBKarla V. Ballman
Karla V. Ballman
Wolters PamelaWolters Pamela
Wolters Pamela
RHRachel S. Heise
Rachel S. Heise
JSJack F Shern
Jack F Shern
BWBrigitte C. Widemann
Brigitte C. Widemann
Purpose: Combined mTOR and MEK inhibition, critical components of the RAS effector pathway underlying the pathogenesis of neurofibromatosis type 1 (NF1)–related tumors, caused regression in a malignant peripheral nerve sheath tumor (MPNST) transgenic mouse model. The primary objective was to determine the clinical benefit rate in patients with unresectable/metastatic MPNST. Patients and Methods: The study design was a multi-institutional, open-label, Simon two-stage, phase II study of the MEK inhibitor selumetinib and mTOR inhibitor sirolimus. Patients ≥12 years with histologically confirmed MPNST received selumetinib 50 mg twice daily and sirolimus 4 mg once daily, in continuous 28-day cycles. Correlative studies evaluated patient-reported pain, immune signature in peripheral blood, and cell-free DNA (cfDNA). Results: A total of 21 heavily pretreated patients [seven females; median age, 41 years (range, 16–72); and 14 with NF1] with advanced disease enrolled at five participating sites. Clinical benefit was observed in only one of seven in stage 1 and one of 14 patients in stage 2. The median number of cycles was two (range, 1–6). Most common adverse events (AE) were grade ≤2 gastrointestinal toxicity, acneiform rash, hypertriglyceridemia, mucositis, and transaminase elevation. Unlike the preclinical model, early 18F-fluorodeoxyglucose PET scan performed during cycle 1 demonstrated partial metabolic responses in five patients (24%), but these did not correlate with objective responses after cycle 2. cfDNA was able to detect MPNST with the potential to be a biomarker of response. Conclusions: The combination was safe, with manageable and expected AEs, but did not meet study parameters for further evaluation in MPNST. Correlative studies were informative and may guide future therapeutic trials of MPNST.

19 December 2025 in Science Advances
Verified
Journal Article
Open access
RMRasel Al Mahmud
Rasel Al Mahmud
SBSimone Andrea Baechler
Simone Andrea Baechler
ADAnjali Dhall
Anjali Dhall
SSSourav Saha
Sourav Saha
HZHongliang Zhang
Hongliang Zhang
YPYves Pommier
Yves Pommier
Topoisomerase III-beta (Top3b) reduces nucleic acid torsional stress and intertwining generated during RNA and DNA metabolism while protecting the genome from pathological R-loops, which otherwise result in DNA breakage and genome instability. By studying Top3b knockout mice ( Top3b -KO), we find that the loss of Top3b accelerates the development of spontaneous atypical lymphoid hyperplasia and lymphomas arising in spleens and lymph nodes, organs with prominent Top3b expression. Aging Top3b -KO mice also display splenomegaly and systemic immune alterations including neutrophilia and lymphopenia consistent with chronic inflammation. At the molecular level, Top3b deficiency causes genome-wide R-loop accumulation in splenocytes as measured by CUT&Tag sequencing. Increased R-loops are associated with genomic breaks and activation of immune signaling pathways including innate and adaptive immune cell signaling, IL-4 signaling, FAK signaling, and cGAS-STING. In addition, knocking-out Top3b promotes the rapid development of syngeneic EL4 T cell lymphomas. In conclusion, our work implies that Top3b protects from lymphoma, tumorigenesis, and immune dysregulations.